Form 4: Pacira BioSciences Grants CAO Kristen Williams 54,546 RSUs

Pacira BioSciences, Inc. Chief Administrative Officer Kristen Williams was granted 54,546 restricted stock units as part of her compensation.

Summary

• Kristen Williams, Chief Administrative Officer of Pacira BioSciences, Inc., acquired 54,546 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on February 11, 2026.
• The RSUs will vest in four equal annual installments, commencing on February 15, 2027.
• Vesting is contingent upon Ms. Williams' continuous service with the issuer.
• Each RSU provides the contingent right to receive one share of Pacira BioSciences' common stock.
• Following this transaction, Ms. Williams beneficially owns 185,849 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at retention and alignment, with minor future dilution.

Positives

• The grant of restricted stock units aligns the Chief Administrative Officer's interests with long-term shareholder value through future equity vesting.
• The vesting schedule, tied to continuous service, incentivizes executive retention.

Negatives

• The future vesting of these RSUs will result in dilution for existing shareholders as new shares are issued.

Future Outlook

NA

Management Comments

• /s/ Kristen Williams

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, are a standard component of executive compensation packages across the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and align executive interests with shareholder returns, often with multi-year vesting schedules.

Comparison to Industry Standards

• Executive compensation through restricted stock units is a common practice in the biotechnology sector, comparable to companies like Amgen Inc. or Gilead Sciences, Inc., which frequently use equity awards to attract and retain top talent.
• The four-year vesting schedule is typical for such grants, aiming to ensure long-term commitment from key executives.

Related Party Transactions

• The grant of restricted stock units to Kristen Williams, an officer of Pacira BioSciences, Inc., constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of the restricted stock units as new shares are issued.
• Employees: The grant to a key executive may signal stability in the leadership team.

Next Steps

• The restricted stock units will begin vesting in four equal annual installments starting February 15, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not provide new information that would significantly alter the investment thesis for Pacira BioSciences, Inc. The grant aligns executive incentives with long-term performance but introduces minor future dilution, balancing out any immediate impact. Therefore, a 'hold' recommendation is appropriate as this event is largely neutral to the company's fundamental valuation.

Keywords

Pacira BioSciences, PCRX, Kristen Williams, Restricted Stock Units, RSU, Executive Compensation, Beneficial Ownership, Form 4, Equity Grant